A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukaemia.

Trial Profile

A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukaemia.

Completed
Phase of Trial: Phase 0

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Filgrastim (Primary) ; Dexamethasone; Etoposide; Ifosfamide; Mesna
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 19 Mar 2013 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Actual initiation date changed from Jun 2011 to Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top